| Literature DB >> 33951204 |
Anna M Frustaci1, Maria L Pioltelli1, Emanuele Ravano1, Federica Di Ruscio2, Daniela A Campisi2, Massimo Puoti3, Roberto Cairoli1.
Abstract
Entities:
Mesh:
Year: 2021 PMID: 33951204 PMCID: PMC8239616 DOI: 10.1002/hon.2873
Source DB: PubMed Journal: Hematol Oncol ISSN: 0278-0232 Impact factor: 4.850
Characteristics and outcomes of COVID‐19 positive patients
| ID | Age | Sex | Diagnosis | Disease status | NPS | Symptoms | Outcome | Comments |
|---|---|---|---|---|---|---|---|---|
| #1 | 66 | M | BL | First line | Positive | F/RS | Alive | |
| #2 | 28 | F | DLBCL | R/R | Positive | IP | Alive | 2C |
| #3 | 62 | F | DLBCL | R/R | Positive | No | Alive | |
| #4 | 69 | F | PTCL | First line | Positive | IP | Death (PD) | 4C |
| #5 | 79 | M | DLBCL | First line | Positive | F/RS | Alive | |
| #6 | 62 | M | DLBCL | First line | Positive | IP | Alive | |
| #7 | 85 | M | DLBCL | R/R | Positive | IP | Death (COVID) | |
| #8 | 59 | M | DLBCL | First line | Positive | IP | Alive | |
| #9 | 49 | F | DLBCL | First line | Positive | IP | Alive | |
| #10 | 63 | F | FL | First line | Positive | IP | Alive | |
| #11 | 69 | M | HD | R/R | Positive | IP | Alive | 11C |
| #12 | 78 | M | HD | R/R | Positive | No | Alive | |
| #13 | 55 | F | MM | First line | Positive | IP | Alive | |
| #14 | 65 | M | MCL | First line | Positive | IP | Death (COVID) | |
| #15 | 70 | M | PTCL | R/R | Positive | No | Death (PD) | |
| #16 | 69 | F | DLBCL | R/R | Positive | F/RS | Death (COVID + PD) | 16C |
| #17 | 54 | M | MM | R/R | Positive | F/RS | Alive | |
| #18 | 79 | M | ITP | First line | Positive | IP | Death (COVID) | |
| #19 | 73 | M | MM | R/R | Positive | F/RS | Death (COVID + PD) | 19C |
Note: 2C: Delay in chemotherapy administration. Delay in CART infusion. Risk of death for disease progression. 4C: Familiar spread. Husband hospitalized (IP). 11C: Familiar spread. Wife hospitalized (IP). 16C, 19C: No chest CT scan was performed due to rapid deterioration of clinical conditions.
Abbreviations: BL, Burkitt lymphoma; DLBCL, diffuse large B‐cell lymphoma; F, female; F, fever; FL, follicular lymphoma; HD, Hodgkin disease; IP, interstitial pneumonia; ITP, immune thrombocytopenic purpura; M, male; MCL, mantle cell lymphoma; MM, multiple myeloma; NPS, nasopharyngeal swab; PD, progressive disease; PTCL, peripheral T‐cell lymphoma; R/R, relapsed/refractory; RS, respiratory symptoms.